The senate has passed a re-authorization of FDA fee collection and expanding access to unapproved medicines. The passed user authorization bill enables the FDA to continue collecting application processing fees from the pharmaceutical industry until 2022. The right-to-try legislation will allow patients who try unapproved pharmaceuticals to be factored into final FDA approval decisions. This legislation signals an emerging connection between the agency and industry dynamics. Read the full article here.
